As we settle into 2024, we reflect on the significant legal developments of 2023 that hold potential impact on the biologics and biosimilars market. The following is a recap of.
The standard for written description in the life sciences seems to have tightened lately, leading patent applicants to wonder what level of written support and working example data is.
On February 18th, Sigma-Aldrich filed its Opposition to Junior Party's (the University of California, Berkeley; the University of Vienna; and Emmanuelle Charpentier; collectively,.
Explosive growth of antibody technology and therapeutics over the past three decades has driven development of antibody-centric patent case law across several fronts.
ToolGen Files Opposition to CVC Substantive Preliminary Motion No 1 for Priority Benefit | McDonnell Boehnen Hulbert & Berghoff LLP jdsupra.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from jdsupra.com Daily Mail and Mail on Sunday newspapers.